{Reference Type}: Clinical Trial, Phase I
{Title}: Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.
{Author}: Karron RA;San Mateo J;Thumar B;Schaap-Nutt A;Buchholz UJ;Schmidt AC;Bartlett EJ;Murphy BR;Collins PL;
{Journal}: J Pediatric Infect Dis Soc
{Volume}: 4
{Issue}: 4
{Year}: Dec 2015
{Factor}: 5.235
{DOI}: 10.1093/jpids/piu104
{Abstract}: We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.